Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system

被引：52

作者：

Slobod, KS

Taylor, GH

Sandlund, JT

Furth, P

Helton, KJ

Sixbey, JW

机构：

[1] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA

[2] St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA

[3] St Jude Childrens Res Hosp, Dept Diagnost Imaging, Memphis, TN 38105 USA

[4] Univ Tennessee, Dept Pediat, Memphis, TN USA

[5] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA

[6] Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71105 USA

来源：

LANCET | 2000年 / 356卷 / 9240期

关键词：

D O I：

10.1016/S0140-6736(00)02879-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Epstein-Barr virus (EBV) targeted therapeutic strategies for viral associated malignant diseases have received only perfunctory consideration, first, because latent herpesviruses have been intractable to antiviral chemotherapy and, second, because the role EBV has in maintenance of the malignant cell phenotype has been uncertain, Two patients with EBV related primary central nervous system lymphoma (PCNSL) in the setting of advanced AIDS, were treated with low dose hydroxyurea based on in vitro anti-EBV activity. The responses obtained here suggest the promise of antiviral approaches in select cancers.

引用

页码：1493 / 1494

页数：2

共 5 条

[1] Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype [J].